Use of PTHrP antagonists for treating renal cell carcinoma
US7727526B2 · kind B2 · utility
0Cited by
1References
12Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Jul 4, 2003 |
| Grant date | Jun 1, 2010 |
| Priority date | — |
| Expiry date | Sep 1, 2023 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K2039/505
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention concerns the use of a PTHrP antagonist for preparing a pharmaceutical composition for treating renal cell carcinoma (RCC) in a mammal and in particular in a human subject. Advantageously, the invention is of particular interest for inhibiting or reducing tumour growth and/or metastasis formation in kidney cancer and its metastatic developments, in particular in the lung and the liver.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.